Analytical Data
-
Gene name
CACNa1E
- Application
-
Alternative Names
BII; CACNL1A6; CACH6; Brain calcium channel II; Calcium channel, L type, alpha-1 polypeptide, isoform 6; Voltage-gated calcium channel subunit alpha Cav2.3
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q61290
-
Expression Region
Gly246~Trp327
-
Molecular Weight
42kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CACNa1E, a member of the voltage-gated calcium channel family, plays a crucial role in calcium ion influx that is essential for various physiological processes, including neurotransmitter release, muscle contraction, and gene expression. This channel is predominantly expressed in the central and peripheral nervous systems, as well as in some endocrine tissues, linking its function to neurological signaling and hormone secretion. Research into CACNa1E has gained momentum due to its involvement in certain neurological disorders and its potential as a therapeutic target. Mutations or dysregulation of CACNa1E can lead to conditions such as episodic ataxia, seizures, and other calcium channelopathies. Investigating the properties and biological functions of CACNa1E through the production of recombinant proteins provides insights into its structural dynamics, pharmacological characteristics, and interactions with various signaling pathways. The expression and purification of functional CACNa1E proteins facilitate a deeper understanding of their ion conduction properties and the molecular mechanisms underlying their role in health and disease. Advances in this area of research hold promise for developing targeted treatments that may alleviate symptoms associated with CACNa1E-related disorders, making it a significant focus of contemporary neuroscience and pharmacology studies.
